Precision dosing in Allergen Immunotherapy in collaboration with CamAllergy, UK
| Reference number | |
| Coordinator | OnDosis AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - September 2025 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Important results from the project
The project met its goal to prepare OnDosis and Camallergy for a clinical trial of the combination product. Collaboration deepened with a clear distribution of responsibilities. We achieved Design Input/SRS, developed and verified customized software, and a successful PoC on dose-dispensing accuracy. Other results include stronger tech transfer and process control (cartridge filling), verification data for CTA/IND, and a UK early-access path (Reg. 167/EAMS).
Expected long term effects
The expected long-term effects include faster path to trials and market through home-based up-dosing with fewer clinic visits, better adherence and freed capacity. A UK early-access route (Regulation 167/EAMS) can deliver earlier patient benefits. Strengthened tech transfer and process control improve the scalability and attract investment. Methods are transferable to other allergens, enables real-world evidence, and boost Swedish life-science export.
Approach and implementation
The project was carried out as planned. Activities were appropriate and executed in the planned sequence with Camallergy. Schedule and budget were met. Collaboration worked well with clear distribution of responsibilities and mutual support when issues arose. Strong outcomes in requirements definition, technical development (device–formulation integration), adaptation of the manufacturing process, and regulatory documentation. No major external disruptions occurred.